New hope for treating demyelinating diseases
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
01-Feb-2023 -
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture ...
funding